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Abstract
Glucose enters eukaryotic cells via two types of membrane-associated carrier proteins, the Na+/glucose cotransporters (SGLT) 
and the facilitative glucose transporters (GLUT). The SGLT family consists of six members. Among them, the SGLT1 and SGLT2 
proteins, encoded by the solute carrier genes SLC5A1 and SLC5A2, respectively, are believed to be the most important ones 
and have been extensively explored in studies focusing on glucose fluxes under both physiological and pathological conditions. 
This review considers the regulation of the expression of the SGLT promoted by protein kinases and transcription factors, as 
well as the alterations determined by diets of different compositions and by pathologies such as diabetes. It also considers 
congenital defects of sugar metabolism caused by aberrant expression of the SGLT1 in glucose-galactose malabsorption and 
the SGLT2 in familial renal glycosuria. Finally, it covers some pharmacological compounds that are being currently studied 
focusing on the interest of controlling glycemia by antagonizing SGLT in renal and intestinal tissues.
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Glucose is the main source of energy in eukaryotes 
and the main fuel providing energy for regular metabolic 
activity in humans (1). As a polar molecule, glucose is not 
soluble in the plasma membrane and must be transported 
across it by carrier proteins, named glucose transporters. 
Glucose transporters are divided into two families: the 
facilitative diffusion glucose transporters (GLUTs) and the 
Na+/glucose cotransporters (SGLTs) (1). Both GLUTs and 
SGLTs belong to one of the 43 families of solute carrier 
genes (SLC1-SLC43). 
Glucose transporters play an essential role in the main-
tenance of euglycemia, not only by determining glucose 
uptake in all cellular types, but also by releasing glucose 
from the liver when circulating glucose levels decrease. In 
addition, these transporters are responsible for absorbing 
glucose from the diet in the intestine, and for reabsorbing 
the glucose from the glomerular filtrate in kidneys (2). 
Transepithelial glucose transport in cells from the small 
intestine, the renal proximal tubules and salivary gland 
ducts occurs by the coordinate action of SGLTs allowing 
glucose influx through the luminal membrane, and GLUTs 
allowing glucose efflux through the basolateral membrane 
(2). This process, in which SGLTs play a key role, will be 
detailed below.
This review will focus on the SGLTs, which are extremely 
important for survival, not only by assuring energy substrate 
taken from food (glucose absorption), but also by preventing 
its loss in urine and/or saliva (glucose reabsorption).
SGLTs
SGLTs constitute a large family of membrane proteins 
involved in the transport of glucose, amino acids, vitamins, 
osmolytes, and some ions across the brush border mem-
brane of the small intestine epithelium and the renal proximal 
tubules. Although 6 isoforms of Na+/glucose cotransporters 
have been described, the SGLT1 and SGLT2 proteins, 
encoded by the solute carrier genes SLC5A1 and SLC5A2, 
respectively, are believed to be the most important ones 
and have been extensively explored in studies focusing on 
glucose fluxes under both physiological and pathological 
conditions.
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Crane et al. (3) were pioneering researchers who pos-
tulated that active glucose transport across the intestinal 
epithelium is driven by the sodium gradient across the 
membrane, by means of an Na+/glucose cotransport (3). 
Actually, subsequent studies revealed that the sodium 
electrochemical potential gradient across the brush border 
membrane promotes sodium influx, providing the energy, 
which drives glucose into the enterocytes. Sodium that en-
ters the cell along with glucose is then transported into the 
interstitium by Na+/K+ ATPase at the basolateral membrane, 
maintaining the electrochemical gradient for luminal sodium 
influx. Thus, the energy for the whole process comes from 
the adenosine-5’-triphosphate (ATP) consumed by Na+/K+ 
ATPase. Glucose accumulating within the enterocyte is then 
transported across the basolateral membrane by facilitative 
diffusion transporters (4). By this process, 1 mole glucose 
and 2 moles sodium are transported across the enterocyte 
from the lumen into the interstitium, this being followed by 
water and 2 moles anions to ensure electroneutrality (4).
SGLT1
SGLT1 is a 75-kDa membrane protein with an Na+/
glucose stoichiometry of 2:1. It contains 14 transmembrane 
α-helices, a single glycosylation site between transmem-
brane helices 5 and 6, and two phosphorylation sites 
between transmembrane helices 6 and 7 and between 
transmembrane helices 8 and 9 (4,5). The NH2 and COOH 
termini are extracellular and intramembrane, respectively, 
and the glucose binding and translocation domains involve 
the five transmembrane segments, which are next to the 
COOH terminus (4).
The SGLT1 protein, encoded by the SLC5A1 gene, is 
located mainly in the intestine, but has also been detected 
in the kidney, parotid and submandibular salivary glands as 
well as in the heart (4,6,7). It has high affinity for glucose, but 
low capacity of transporting it, and is specifically inhibited 
by phlorizin. Furthermore, the cotransporter affinity is the 
same for glucose and galactose (8).
Through the SGLT1, two sodium ions are transported 
for each molecule of glucose. This cotransport is a second-
ary Na+/K+ ATPase-dependent process, able to transport 
glucose into the cell against its concentration gradient (9). 
In the steady state, Na+ ions entering the cell across the 
luminal membrane are pumped out by Na+/K+ ATPase in the 
basolateral membrane. Glucose concentrates within the cell, 
a process that allows it to move downhill to the interstitium 
through the facilitative diffusion transporters (1).
It is believed that Na+ and glucose transport by the 
SGLT1 occurs by a sequential mechanism in which two 
Na+ ions on the extracellular side bind to the transporter 
right before glucose, inducing a conformational change 
in the glucose binding site and increasing the transporter 
affinity for this substrate. Then, another conformational 
change determines the shift of the Na+ and glucose bind-
ing sites to the inner surface of the membrane, with the 
glucose molecule and immediately after the two Na+ ions 
being released within the cell (4,8). Within this process, the 
SGLT1 protein is able to recycle about one thousand times 
per second at 37°C (4).
In recent years it has been demonstrated that, besides 
the two Na+ ions plus the one glucose molecule, the SGLT1 
protein is also able to transport about 264 H2O molecules. 
The coupled water transport occurs due to changes induced 
by ligands (sodium and glucose) in the protein structure 
during the transport cycle (4,10). The water permeability of 
the SGLT1 is independent of the grade and direction of the 
osmotic gradient (4,10), and 35% of total water transport 
triggered in response to SGLT1 activation is considered 
to be sugar-coupled water transport in Xenopus laevis 
oocytes expressing SGLT1 (10). Another mechanism is 
the osmotic transport of water induced by the intracel-
lular sodium and glucose accumulation near the plasma 
membrane (11), which accounts for 65% of the total water 
transport that occurs in response to the SGLT1 activation 
(4,12). In humans, the current 1 mole glucose absorbed 
per day in the intestine determines absorption of up to 4 
liters of water by the sugar-coupled water transport system. 
Because of that, it is clear that SGLT1 plays an important 
role in water absorption in the brush border membrane of 
enterocytes (4).
SGLT2
The SGLT2 protein was originally described as an amino 
acid cotransporter called Na+-dependent neutral-amino 
acid transporter, SAAT1 (13), but was later recognized 
as a glucose transporter (14). This protein contains 672 
amino acids and its NH2 and COOH termini are extracel-
lular (5). Differently from SGLT1, SGLT2 is a low-affinity 
and high-capacity glucose transporter, which transports 1 
Na+ ion for each glucose molecule. The SGLT2 encoding 
gene (SLC5A2) is predominantly expressed in kidneys, 
but low mRNA expression has also been demonstrated in 
mammary glands, liver, lungs, intestine, skeletal muscle, 
and spleen (15).
SGLT2 is highly expressed in the luminal membrane of 
the S1 segment of the renal proximal tubule. This isoform 
is mainly responsible for glucose reabsorption from the 
glomerular filtrate. In fact, more than 90% of the filtered 
glucose is reabsorbed in the initial segments of the proximal 
tubule via SGLT2 (4,16).
Transepithelial glucose transport
Transepithelial glucose transport involves the two 
classes of glucose transporters, SGLTs and GLUTs. Renal 
glucose reabsorption occurs mainly in the S1 segment of the 
proximal tubule by the coordinated action of the SGLT2 and 
GLUT2 located in the luminal and basolateral membranes, 
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respectively. Only a small and residual amount of glucose 
is reabsorbed in the S3 segment, where SGLT1 is present 
in the luminal membrane, co-expressed with GLUT1 in the 
basolateral membrane (4). Intestinal glucose absorption 
occurs mostly in the duodenum and in the initial portion 
of the jejunum, and involves the co-expression of SGLT1 
and GLUT2 (4). In all these processes, SGLTs present in 
the luminal membrane transport glucose from the lumen 
into the intracellular medium, where glucose accumulates 
generating a gradient that favors its transport through the 
GLUTs in the basolateral membrane, from the cytoplasm 
to the interstitium (4) (Figure 1).
Other SGLTs
Human SGLT3, encoded by the SLC5A4 gene, is con-
sidered to be a glucose-gated ion channel, expressed in 
the intestine, spleen, liver, kidneys, skeletal muscle, and 
cholinergic neurons. It does not transport Na+ or glucose 
when expressed in Xenopus laevis oocytes, but it causes 
the plasma membrane to depolarize in the presence of 
glucose in a saturable, Na+-dependent and phlorizine-
sensitive manner (15,16).
It has been demonstrated that porcine SGLT3 expressed 
in oocytes behaves as an Na+/glucose cotransporter with 
very low affinity for glucose (17). However, in humans, 
SGLT3 is not a functional Na+/glucose cotransporter, but 
seems to work as a glucose sensor in the plasma membrane 
of cholinergic neurons of the enteric nervous system and 
neuromuscular junctions of skeletal muscle (18), where 
plasma glucose variations modulate the membrane potential 
of the neurons.
There are only a few reports on other SGLTs, but it is 
known that SGLT4, encoded by the SLC5A9 gene, is ex-
pressed in the small intestine, kidneys, liver, lung and brain, 
and SGLT5, encoded by the SLC5A10 gene, is expressed 
only in the kidneys. Furthermore, SGLT6, encoded by the 
SLC5A11 gene, is supposed to be a low affinity D-glucose 
transporter in the small intestine (4).
SGLTs and protein kinases
Protein kinases (PK) may regulate the activity of mem-
brane transporter proteins either directly or indirectly (19). 
Direct effects occur through phosphorylation of the trans-
porter, thus changing the kinetics of the transporter. It was 
demonstrated in rat small intestines that the activation of 
β-adrenoreceptors induces phosphorylation of SGLT1 via 
PKA, enhancing the cotransporter function, and thus in-
creasing glucose transport (20). Indirect regulations involve 
changes in the rate of the insertion into or retrieval from the 
plasma membrane. Membrane proteins are cotranslationally 
inserted into the endoplasmic reticulum and processed by 
the Golgi apparatus, where vesicles are formed to deliver 
the proteins to the plasma membrane (20). Hirsch et al. 
(19) have demonstrated in Xenopus laevis oocytes that PK 
regulate the SGLT1-induced glucose transport by control-
ling the distribution of transporters between intracellular 
compartments and the plasma membrane. Activation of 
PKA and PKC, respectively, increases and decreases the 
maximum rate of Na+/glucose transport, an event accom-
panied by an increase and decrease, respectively, in the 
plasma membrane SGLT1 protein content (19). However, 
SGLT1 translocation seems to be independent of the phos-
phorylation of potential phosphorylation sites present in 
the transporter (19). Although some investigators propose 
that these effects might be extended to other isoforms of 
SGLTs (4,19), to our knowledge, these mechanisms were 
demonstrated only for the SGLT1 protein.
As a physiological consequence of these rapid regula-
tions of SGLT1, we hypothesize that the anticipative and 
Figure 1. Glucose transport across the renal proximal tubule 
and proximal intestine. Glucose is transported across the luminal 
membrane by sodium/glucose cotransporters 1 and 2 (SGLT1 
and SGLT2) and then exits through the basolateral membrane by 
the facilitative glucose transporters 1 and 2 (GLUT1 and GLUT2). 
The renal cells represent epithelial cells of the S1 and S3 seg-
ments of the renal proximal tubule, respectively; the intestinal 
cells represent enterocytes from the proximal intestine. SGLT1 
and SGLT2 in the luminal membranes and GLUT1 and GLUT2 
in the basolateral membranes are shown, indicating the glucose 
flow through the epithelial cell.
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the postprandial increases in β-adrenergic activity could 
contribute to enhancing intestinal glucose absorption by 
translocating SGLT1.
Transcriptional regulation of SGLTs
Among the transcription factors reported to participate 
in the regulation of SGLT expression, hepatocyte nuclear 
factors 1α and 1β (HNF-1α and HNF-1β) can be cited as 
essential regulators of SGLT1 expression (21). HNF-1α 
and HNF-1β were originally characterized as liver-specific 
transcription factors that regulate several genes (22) and 
were later also implicated in tissue-specific gene regulation 
in the pancreas, kidney, and intestine. HNF-1α and HNF-1β 
are developmentally expressed, and their transcriptional 
effects have been initially related directly to the degree of 
protein expression. 
HNF-1α and HNF-1β contain an NH2-terminal di-
merization domain, and they bind to DNA as homodimers 
or heterodimers. Isoforms α and β have been reported to 
have distinct transcriptional activity, and thus the pattern 
of dimerization plays a key role in the final effect on the 
transcription of target genes (23,24). In the SLC5A1 gene 
promoter, there are two cis-regulatory elements for HNF-
1α/β, which were demonstrated to be functional by transient 
promoter assays (21,25,26). The ratio of HNF-1α and 
HNF-1β dimerization is particularly important in modulating 
the transcription of SGLT1. Homodimers of HNF-1α are as-
sociated with increased SGLT1 transcription, whereas het-
erodimers of HNF-1α/β decrease SGLT1 transcription (23). 
A circadian periodicity of intestinal SGLT1 expression was 
reported in the intestines of ad libitum-fed rats: the higher 
transcriptional rate correlated with HNF-1α homodimers in 
the morning (10:00 h) and the lower rate with the appear-
ance of HNF-1α/β heterodimers in the afternoon (16:00 h) 
(23). However, the mechanism by which the dimerization 
process changes was not determined. 
An additional mechanism that regulates the HNF-1 
transcriptional activity is based on its interaction with other 
proteins. By analyzing DNA sequences implicated in the 
specific transcriptional regulation of genes by the liver, key 
nuclear proteins have been identified, such as HNF-3, HNF-
4, HNF-6, CCAAT/enhancer binding protein (C/EBP), and 
D binding protein (DBP), which can cooperatively enhance 
the transcriptional activity of HNF-1α and/or HNF-1β (24,27). 
HNF1-α can also interact with caudal-type homeobox protein 
2 (CDX2) and GATA-binding protein (GATA) family members 
to regulate the expression of some intestinal genes (21). 
Additionally, proteins from the Sp1 family of transcription 
factors, which bind in GC boxes, in the presence of HNF-1 
also act synergistically by up-regulating the transactivation 
of the promoter of target genes (25). Finally, an important 
role was attributed to the enhancer of rudimentary homolog 
(erh) protein, which, by interacting with the dimerization 
cofactor of HNF-1 (coactivator DCoH), represses the HNF-
1 transcriptional activity (28). Most of these cooperative 
mechanisms have already been reported to modulate the 
expression of the SGLT1 gene (21,25). 
All interactions described above reveal how widespread 
and complex the HNF-1 transcriptional regulations are. 
However, little is known about the mechanisms that control 
these interactions. In this regard, the inhibition of protein 
phosphatases 1/2A in Caco-2 cells has been shown to 
enhance HNF-1α/β phosphorylation, decreasing their DNA-
binding capacity, and thus repressing the expression of the 
gene encoding sucrase-isomaltase (29). Furthermore, the 
mutation of the HNF-1 binding site results in the decrease 
of the cAMP/PKA-induced HNF-1 promoter activity in 
HepG2 cells, indicating that this pathway is involved in the 
transcriptional activity (27). 
Fasting- and refeeding- as well as glucose- and insulin-
induced regulation of HNF-1 transcriptional activity have 
been reported mainly in the liver and intestine. Most of 
these studies involved genes related to glucose metabolism, 
including the SLC5A1 gene that codes for the SGLT1 pro-
tein (21,23,26,27,29). However, the role of dietary proteins 
or lipids, as well as of insulin and/or its counterregulatory 
hormones, on HNF-1 transcriptional activity is unknown. 
Little is known about HNF-1 regulation of the SLC5A2 
gene, which codes for the SGLT2 protein. Impaired renal 
tubular glucose reabsorption was observed in HNF-1α-
deficient mice, suggesting that this transcription factor 
also regulates renal SGLT2 expression (30). Additional 
investigations confirmed decreased SGLT2 expression 
in renal tubular cells of HNF-1α-deficient mice (31). After-
wards, it was shown that HNF-1α directly controls SGLT2 
expression in mouse and man (32). More recently, we 
have demonstrated that increased HNF-1α expression and 
binding activity in the SLC5A2 promoter is involved in the 
diabetes-induced overexpression of SGLT2 (33). Moreover, 
it was observed that diabetes-induced changes in HNF-1α 
activity and SGLT2 expression are reversed by lowering 
glycemia, independently of insulinemia (33), indicating that 
glucose is a major modulator of this transcriptional activity, 
as described for SGLT1. 
SGLTs and diet
It has been reported for a long time that increased 
dietary sugar enhances the intestinal sodium-dependent 
glucose transport, suggesting that SGLT1 expression may 
be increased (34). In fact, alterations in SGLT1 mRNA and 
protein expression as a consequence of dietary carbohy-
drate content were reported in ruminant animals (35,36). 
In addition to induction by dietary carbohydrate, intestinal 
expression of SGLT1 exhibits circadian periodicity in its 
activity. SGLT1 mRNA levels in rats vary, with the maximum 
abundance occurring near the onset of dark and the mini-
mum near the onset of light, variations that are preceded 
~6 h before by parallel changes in transcriptional activity, 
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as described above (23). Furthermore, since the daily varia-
tion in SGLT1 activity persists in the absence of food, this 
variation has been described as an anticipatory response 
and is regulated at the transcriptional level (23). 
Sodium intake also induces important changes in the 
intestinal and renal glucose cotransporters. Some studies 
conducted by us in rats have found a significant decrease in 
SGLT1 mRNA in the upper small intestine with high salt intake. 
Besides, SGLT1 mRNA increased in the middle segments 
with low salt intake. These results correlate with a decreased 
mRNA half-life in the upper segment (on high salt) and an 
increased half-life in the middle segment with low salt intake 
(37). Nevertheless, this regulation was not accompanied by 
alterations in intestinal glucose absorption (37).
In our laboratory, we have also demonstrated that 
a high sodium diet increases the expression of SGLT2, 
GLUT2 and GLUT1 in renal proximal tubules (38). In the 
renal cortex from rats fed a high sodium diet, the very high 
sodium filtration rate improves the cellular glucose influx 
in the early S1 segment. Most of the filtered glucose flows 
rapidly into the epithelial cells in this segment and the 
high-capacity/low-affinity GLUT2 transporter cannot propor-
tionally increase the cellular efflux of glucose. Therefore, 
the S1 epithelial cells may be temporarily submitted to a 
high glucose concentration, which is enough to determine 
the increase of SGLT2 and GLUT2. On the other hand, 
although the luminal sodium concentration is also very 
high in the S3 segments of high salt-fed rats, the modula-
tion of the glucose transporters is not the same as that in 
the S1 segments. The SGLT1 mRNA remains unchanged, 
whereas the GLUT1 protein strongly increases (38). This 
may be explained by the intracellular glucose concentration 
(39), which could be very low in S3 epithelial cells. Since 
the high filtration rate of sodium provides almost complete 
glucose reabsorption in S1 segments, no substrate would 
be available for reabsorption in the S3 territory. This may 
occur despite high sodium concentration and consequently 
intracellular glucose may decrease.
A diet-induced mechanism of SGLT1 expression has 
been recently described, involving the intestinal luminal 
glucose content and a sugar sensor located at the luminal 
membrane of the enterocyte. It has been demonstrated that 
the sweet taste receptor subunit T1R3 and the taste G pro-
tein gustducin, expressed in enteroendocrine cells, underlie 
cellular sugar sensing (40), triggering a signal linked to the 
cAMP-PKA pathway, which eventually leads to enhance-
ment of SGLT1 mRNA and protein expression (35).
SGLTs and diabetes
Dyer et al. (41) have reported that brush border Na+/
glucose cotransport SGLT1 mRNA and protein levels in 
duodenal biopsies are 3- to 4-fold higher in diabetic sub-
jects than in controls. They have concluded that there is an 
increased capacity to absorb glucose in diabetic subjects 
and that this is due to both a rise in transporter expression 
and structural changes in the brush border membrane. 
In diabetic kidneys of rats with both spontaneous and 
pharmacologically induced diabetes, there is increased 
transtubular glucose flux accompanied by increased SGLT2 
and GLUT2 expression (33,42-44). This increased glucose 
transporters expression is part of a regulatory mechanism, 
which intends to avoid glucose loss. However, it also results 
in increased glucose concentration in the proximal tubule 
interstitium, favoring the development of glomerulosclerosis 
and nephropathy in uncontrolled diabetes (45,46).
It is important to emphasize that alterations in SGLT 
expression in diabetes involve mechanisms of regulation 
at the transcriptional level, as recently demonstrated by 
studies from our laboratory using alloxan-induced diabetic 
rats. In those animals, diabetes increased both SGLT2 and 
HNF-1α mRNA expression and there was a correlation 
between the expression of SGLT2 and HNF-1α binding to 
the SGLT2 promoter in the renal cortex, as demonstrated 
by both electrophoretic mobility and chromatin immuno-
precipitation (ChIP) assays (33).
An important public health issue related to diabetes 
concerns the diabetes-associated oral health complications, 
which include xerostomia, periodontal diseases, increased 
incidence and severity of caries, tooth loss, and candidi-
asis (47). These alterations may be linked to salivary gland 
dysfunctions, such as reduced salivary flow rate (48) and 
altered composition of the saliva, e.g., increased glucose 
concentration (49).
Recent studies have made important contributions to this 
area, showing that, SGLT1 mRNA expression increases in 
the parotid and submandibular glands of diabetic rats with 
decreased basal salivary secretion. Furthermore, SGLT1 
protein expression increases in the luminal membrane of 
ductal cells, a process that can exacerbate water reabsorp-
tion from primary saliva (7). Considering the ability of SGLT1 
to act as a water pump in salivary ducts, this protein probably 
regulates salivary flow, and changes in its expression may 
alter the secreted volume of saliva. All of these functional 
and molecular changes contribute to explaining the reduced 
salivary flow of diabetic subjects and, importantly, they are 
all reversed by insulin therapy (7).
Genetic disorders involving the SLC5A1 and 
SLC5A2 genes
There are two types of genetic disorders involving the 
Na+/glucose cotransporters: glucose-galactose malabsorp-
tion (GGM, OMIM 182380) and familial renal glycosuria 
(FRG, OMIM 233100), both involving a single gene muta-
tion.
Patients with GGM present little or no renal glycosuria 
at all, which is in accordance with the limited role of SGLT1 
and a much larger one of SGLT2 in the kidney. This disease 
was reported simultaneously by a group from Sweden and 
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another one from Belgium, in 1962. Severe diarrhea and de-
hydration occur due to water retention in the intestinal lumen, 
caused by the osmotic loss generated by non-absorbed 
glucose, galactose and sodium in the intestine (50). This 
recessive homozygous autosomal disease is rare and usu-
ally results from consanguineous relationships. Mutations 
in the coding sequence of the SGLT1 gene are responsible 
for this disease (51), characterized by neonatal onset of 
watery and acidic diarrhea, which becomes fatal within a few 
weeks unless glucose- and galactose-containing nutrients 
are removed from the diet (51). 
FRG is a rare benign genetic condition of the kidneys 
characterized by an isolated defect in glucose reabsorp-
tion. FRG patients present various degrees of polyuria and 
polydipsia and the urinary loss of glucose occurs even in 
normoglycemia. Individuals are homozygous or compound 
heterozygous for an SGLT2 mutation. Approximately 21 
different gene mutations have been described for SGLT2, 
leading to persistent renal glycosuria, with glucose excre-
tion of up to 160 g/day (52). At the higher level of excretion, 
there is a complete absence of glucose reabsorption from 
the glomerular filtrate (52,53).
SGLTs as therapeutic targets
Oral rehydration therapy (ORT) was the first therapeu-
tic approach based on the sodium/glucose cotransporter 
capacity to induce water transport, as a consequence of 
the intestinal sodium/glucose cotransport (54). ORT is an 
inexpensive, simple and surprisingly effective treatment 
in which sodium and glucose are offered together with 
water for intestinal absorption. As a consequence of the 
sodium and glucose cotransport through SGLT1 in the 
apical membrane of enterocytes, water is highly absorbed 
by both direct cotransport and sodium/glucose-induced 
osmosis. Stoichiometry of SGLT1 determines that recovery 
of 2 moles sodium for each mole of glucose absorbed is 
accompanied by 6 to 8 liters of water (4). This therapy saves 
countless lives in children afflicted with infectious diarrhea, 
and has been considered the greatest medical contribution 
to human health in the 20th century (54). 
More recently, SGLT1 has been targeted for diabetic 
therapy. By blocking glucose reabsorption in the proximal 
renal tubule, reduction of glycemia might be achieved in 
diabetic patients. The first drug developed for this purpose 
was T-1095 (55), a phlorizin analogue, which is absorbed in 
the intestine, converted to its active form in the liver, and then 
filtered by the kidney where it blocks glucose reabsorption 
through SGLT2 and SGLT1. However, because of the side 
effects caused by the inhibition of SGLT1 in other territories, 
this drug could not be indicated for clinical use (56).
Specific SGLT2 inhibitors have been studied as possible 
options for diabetes treatment in the future. One example 
is dapagliflozin (BMS-512148), a compound containing 
C-glycosylation, which confers on it a longer half-life than 
that of phlorizin (57). In addition, compared to SGLT1, it is 
1220-fold more selective for SGLT2, whereas phlorizin is 
only 10-fold more selective (58). In vitro studies have indi-
cated a comparable inhibitory potency against rat SGLT2 
or human SGLT2. Dapagliflozin administration to diabetic 
rats resulted in a 55% reduction in blood glucose 5 h after 
a single dose (58).
Another selective drug being tested for the treatment 
of hyperglycemia and/or obesity in patients with type 1 or 
type 2 diabetes is Sergliflozin (KGT-1251). It is a competitive 
SGLT2 inhibitor able to enhance glucose and energy loss 
through the urine. Based on the observation that individu-
als with familial renal glycosuria maintain normal long-term 
kidney function, it is believed that this mode of action will 
not adversely affect renal function (59). Even better, the 
drug might prevent the development of glomerulosclerosis 
by reducing the interstitial glucose concentration in the 
cortical area. 
Intense research has led to the discovery of novel SGLT 
inhibitors, each with different chemical, pharmacodynamic 
and pharmacokinetic profiles (60) and some will probably 
be available for clinical use soon. 
Perspectives
The extensively growing knowledge about SGLT1 and 
SGLT2 has extended their physiological role in the tissues 
where they are expressed, as well as their participation in 
the pathophysiology of several diseases. As a therapeutic 
target, SGLT1 and SGLT2 selective agonists and antago-
nists should make remarkable contributions to human health 
in the not too distant future. 
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